1.
Adefovir (Hepsera): Nucleotide reverse transcriptase inhibitor useful in HBV patients that have developed resistance to lamivudine.
2.
Alpha-Interferons: affect viral replication, indicated for Hep B,C,D, can give IV, IM, or SC. Flu-like side effects.
3.
Combination therapy: Shown to decrease drug resistance but not to be more effective in treatment.
4.
Common side effects of antivirals: Headache, nausea, vomitting, diarrhea, rash, fever, fatigue, lethargy.
5.
Entecavir (Baraclude): Guanosine nucleoside analog. More potent than Lamivudine and adefovir. HBV use. Can elevate LFTs.
6.
Goal of hepatitis treatment: Treat and suppress viral replication before liver damage is extensive
7.
hepatitis A treatment: can use immunoglobulin if known to be within 2 weeks of exposure
8.
hepatitis a vaccine: indicated for age 1yr or older with risk factors
9.
Lamivudine (Epvir): Reverse transcriptase inhibitor, HBV, patients can become resistant to this treatment. Highest in safety and patient tolerance.
10.
PEGinterferon: Polyethylene glycol preparation of interferon that slows the rate of absorption, making treatment more effective, side effects lessened, once weekly administration.
11.
Ribavirin (Copegus, Rebetol): Nucleoside analogue, use with peginterferon. This drug blunts viral replication. HCV use.
12.
Successful HBV treatment: loss of HBeAg status and seroconversion to anti-HBeAg. NO CURE FOR HBV.
13.
Telbivudine (Tyzeka): HBV specific, drug resistance common, can elevate cpk and cause lactic acidosis.
14.
Tenofovir (Viread): Reverse transcriptase inhibitor, chronic HBV